Healio (9/5, Mahoney) reports, “High-dose psilocybin showed the potential to treat depressive symptoms, although the effect size appeared small and comparable to that of escitalopram, according to results of a network meta-analysis.” The researchers “performed a sensitivity analysis that included only patients with major depressive disorder and found that the relative effects of escitalopram, ayahuasca and high-dose psilocybin had better responses than placebo in antidepressant trials.” The findings were published in The BMJ.

Related Links:

— “High-dose psilocybin may help treat depressive symptoms, with small effect size,”Moira Mahoney, Healio, September 5, 2024

MedPage Today (9/4, DePeau-Wilson ) reports, “Having a medical condition was associated with an increased risk of suicide in a dose-response-like manner, such that the higher the burden of disability, the higher the risk of suicide, according to an observational study in Denmark.” An analysis of over “6.6 million people found that nine medical condition categories including 31 specific conditions were associated with a statistically significant increased risk of suicide, with the exception of endocrine disorders.” Researchers found “the associations were most pronounced for gastrointestinal conditions… cancers…and hematological conditions.” The findings were published in JAMA Psychiatry. “ Individuals with mental disorder requiring psychiatric hospital treatment appear to be at such elevated risk of suicide that additional disability associated with medical conditions has little impact in this regard.”

Related Links:

— MedPage Today (requires login and subscription)

MedPage Today (9/3, Monaco ) reports, “Two new studies published in JAMA Internal Medicine do not support a previously reported association between GLP-1 receptor agonists and a signal for suicidal ideation.” In one “analysis of nearly 300,000 new users of a GLP-1 agonist or SGLT2 inhibitor in Sweden and Denmark, primarily for diabetes, rates of suicide death over 2.5 years were not significantly different between groups, reaching 0.23 and 0.18 events per 1,000 person-years, respectively.” In the second study, researchers “pooled data from several of the STEP trials that supported semaglutide’s (Wegovy) weight-loss indication.” The “analysis showed that in STEP 1, 2, and 3, depression scores on the Patient Health Questionnaire-9 were lower at study end for patients on a 2.4-mg dose of semaglutide versus placebo recipients.”

Related Links:

— MedPage Today (requires login and subscription)

Psychiatric News (9/3) reports “cannabis use disorder and frequent cannabis use are linked to greater absenteeism at work, a study” found. Study “participants who used cannabis in the past month had a mean 1.47 days of missed work because of illness or injury, compared with 0.95 days for those who never used cannabis.” The findings were published in the American Journal of Preventive Medicine.

Related Links:

— “Cannabis Use Linked to Absenteeism at Work, Psychiatric News, September 3, 2024

The New York Times (9/1, Silver-Greenberg , Thomas) reported “Acadia Healthcare is one of America’s largest chains of psychiatric hospitals,” and “since the pandemic exacerbated a national mental health crisis, the company’s revenue has soared.” However, “a New York Times investigation found that some of that success was built on a disturbing practice: Acadia has lured patients into its facilities and held them against their will, even when detaining them was not medically necessary.” According to records, “in at least 12 of the 19 states where Acadia operates psychiatric hospitals, dozens of patients, employees and police officers have alerted the authorities that the company was detaining people in ways that violated the law.” In a number of “cases, judges have intervened to force Acadia to release patients.”

Related Links:

— “The New York Times (requires login and subscription)